• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.

作者信息

Fan Jiansheng, Zhuang Xinlei, Yang Xiaoyue, Xu Yingchun, Zhou Zhan, Pan Liqiang, Chen Shuqing

机构信息

Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

出版信息

Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.

DOI:10.1038/s41392-021-00666-5
PMID:34475375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8413295/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a19b/8413295/f46fa7db4241/41392_2021_666_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a19b/8413295/f46fa7db4241/41392_2021_666_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a19b/8413295/f46fa7db4241/41392_2021_666_Fig1_HTML.jpg

相似文献

1
A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.一种多价双特异性靶向表皮生长因子受体（EGFR）的纳米抗体药物偶联物在实体瘤模型中显示出强大的抗癌活性。
Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.
2
A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties.毕赤酵母和大肠杆菌中表达的抗 EGFR 纳米抗体的比较研究和评估作为抗肿瘤部分。
Protein Expr Purif. 2021 Aug;184:105888. doi: 10.1016/j.pep.2021.105888. Epub 2021 Apr 13.
3
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.抗体药物偶联物靶向 DDR1 在结直肠癌小鼠模型中具有抗肿瘤作用。
Mol Oncol. 2019 Sep;13(9):1855-1873. doi: 10.1002/1878-0261.12520. Epub 2019 Jul 22.
4
Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.发现一种新型的 EGFR 靶向抗体药物偶联物 SHR-A1307，用于治疗对抗 EGFR 治疗耐药或难治的实体瘤。
Mol Cancer Ther. 2019 Jun;18(6):1104-1114. doi: 10.1158/1535-7163.MCT-18-0854. Epub 2019 Apr 8.
5
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.一种双靶向抗 EGFR 纳米抗体能有效抑制实体瘤生长。
Int J Cancer. 2011 Oct 15;129(8):2013-24. doi: 10.1002/ijc.26145. Epub 2011 Aug 8.
6
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.在黑素瘤异种移植模型中靶向和研究抗 IL13Rα2 抗体及抗体药物偶联物的药效学。
MAbs. 2021 Jan-Dec;13(1):1958662. doi: 10.1080/19420862.2021.1958662.
7
Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).靶向表皮生长因子受体（EGFR）二聚体界面的人源化纳米抗体的制备与表征
Protein Expr Purif. 2019 May;157:57-62. doi: 10.1016/j.pep.2019.02.003. Epub 2019 Feb 5.
8
Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.近红外光免疫疗法靶向 EGFR 脱落——为胶质母细胞瘤治疗带来新曙光。
Int J Cancer. 2018 Jun 1;142(11):2363-2374. doi: 10.1002/ijc.31246. Epub 2018 Jan 19.
9
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects.一种跨物种反应性 TIGIT 阻断抗体 Fc 依赖性赋予强大的抗肿瘤作用。
J Immunol. 2020 Oct 15;205(8):2156-2168. doi: 10.4049/jimmunol.1901413. Epub 2020 Sep 4.
10
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.新型 CD16A 特异性固有免疫细胞衔接子 AFM24 对表皮生长因子受体阳性肿瘤的临床前评估。
MAbs. 2021 Jan-Dec;13(1):1950264. doi: 10.1080/19420862.2021.1950264.

引用本文的文献

1
It's a match: use of the radionuclide theranostic pair La/Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies.成功匹配：放射性核素诊疗对La/Ac用于表皮生长因子受体靶向单域抗体的放射药理学特性研究
EJNMMI Radiopharm Chem. 2025 Jun 19;10(1):31. doi: 10.1186/s41181-025-00354-7.
2
Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications.开发一种用于单光子发射计算机断层扫描（SPECT）成像及潜在癌症治疗应用的新型抗癌胚抗原相关细胞黏附分子5（CEACAM5）单域抗体（VHH）。
Eur J Nucl Med Mol Imaging. 2025 May 13. doi: 10.1007/s00259-025-07321-z.
3
Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors.

本文引用的文献

1
Nanobody-A versatile tool for cancer diagnosis and therapeutics.纳米抗体——癌症诊断和治疗的多面手。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1697. doi: 10.1002/wnan.1697. Epub 2021 Jan 20.
2
Improved GPCR ligands from nanobody tethering.通过纳米抗体连接提高 G 蛋白偶联受体配体的亲和力。
Nat Commun. 2020 Apr 29;11(1):2087. doi: 10.1038/s41467-020-15884-8.
3
Complement is activated by IgG hexamers assembled at the cell surface.补体通过组装在细胞表面的 IgG 六聚体激活。
开发一种靶向上皮细胞黏附分子（EpCAM）和紧密连接蛋白3（CLDN3）的双特异性抗体药物偶联物用于治疗多种实体瘤。
Exp Hematol Oncol. 2025 Mar 8;14(1):33. doi: 10.1186/s40164-025-00624-9.
4
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds.双特异性抗体的应用进展：收获早期播种的成果并播下新的种子
BioDrugs. 2025 Jan;39(1):75-102. doi: 10.1007/s40259-024-00691-0. Epub 2024 Dec 13.
5
Antibody drug conjugates in the clinic.临床中的抗体药物偶联物。
Bioeng Transl Med. 2024 May 4;9(6):e10677. doi: 10.1002/btm2.10677. eCollection 2024 Nov.
6
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.纳米抗体的发现：过去五年中它们的应用和潜力的全面综述。
J Nanobiotechnology. 2024 Oct 26;22(1):661. doi: 10.1186/s12951-024-02900-y.
7
Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.作为抗体药物偶联物的单域抗体：从前景到实践——一项系统综述
Cancers (Basel). 2024 Jul 27;16(15):2681. doi: 10.3390/cancers16152681.
8
Unlocking the potential of bispecific ADCs for targeted cancer therapy.解锁双特异性 ADC 用于靶向癌症治疗的潜力。
Front Med. 2024 Aug;18(4):597-621. doi: 10.1007/s11684-024-1072-8. Epub 2024 Jul 23.
9
Bispecific antibody drug conjugates: Making 1+1>2.双特异性抗体药物偶联物：实现1+1>2
Acta Pharm Sin B. 2024 May;14(5):1965-1986. doi: 10.1016/j.apsb.2024.01.009. Epub 2024 Jan 20.
10
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.一种人源化的三聚体 Nectin-4 靶向纳米抗体药物偶联物在胃癌中显示出强大的抗肿瘤活性。
J Nanobiotechnology. 2024 May 16;22(1):256. doi: 10.1186/s12951-024-02521-5.
Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.
4
The quest to overcome resistance to EGFR-targeted therapies in cancer.克服癌症中表皮生长因子受体靶向治疗耐药性的探索。
Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7.
5
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.补体激活介导西妥昔单抗抑制非小细胞肺癌肿瘤生长在体内。
Mol Cancer. 2010 Jun 7;9:139. doi: 10.1186/1476-4598-9-139.